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enetic Polymorphisms of Platelet Glycoprotein Ia
nd the Risk for Premature Myocardial Infarction
ffects on the Release of sCD40L During
he Acute Phase of Premature Myocardial Infarction
haralambos Antoniades, MD, Dimitris Tousoulis, MD, PHD, FACC, Carmen Vasiliadou, BSC, MSC,
lli Stefanadi, MD, Kyriakoula Marinou, MD, Christodoulos Stefanadis, MD, FACC, FESC
thens, Greece
OBJECTIVES The aim of this research was to evaluate the effect of genetic polymorphisms C807T and
G1648A of platelet glycoprotein Ia (GPIa), on the risk for myocardial infarction (MI) and on
the release of soluble CD40 ligand (sCD40L) during the acute phase of MI and one year after
the event.
BACKGROUND C807T and G1648A polymorphisms affect the density of GPIa on platelet surface, but their
effect on the risk for MI and the release of sCD40L is unknown.
METHODS The study population consisted of 219 patients with premature MI and 389 controls. One
year after the event, 67 patients and 232 controls were recalled for the follow-up study.
RESULTS The risk for MI in 807TT was 2.296 (95% confidence interval [CI]: 1.187 to 4.440) p 0.05
versus CC  CT, 2.269 (95% CI: 1.085 to 4.745) p  0.05 versus CC, and 2.135 (95% CI:
1.080 to 4.219) p  0.05 versus CT. During the acute phase of MI, sCD40L was higher in
807CT  TT compared with 807CC (p  0.01), an effect persisting after one year (p 
0.01). The carriage of 807T allele was an independent predictor for sCD40L during the acute
phase of MI (  9.442 [standard error (SE): 2.526], p  0.001) and in the same patients
one year later (  8.282 [SE: 2.044], p  0.001). In healthy individuals, 807T allele was
associated with higher sCD40L levels compared with 807CC (p  0.05), only among those
with von Willebrand factor greater than or equal to median.
CONCLUSIONS Genetic polymorphism C807T increases the risk for premature MI. 807T allele is an
independent predictor for sCD40L levels during the acute phase of premature MI as well as
one year after the event, while it is associated with elevated sCD40L levels in healthy subjects,
only in the presence of high von Willebrand levels. (J Am Coll Cardiol 2006;47:1959–66)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.057© 2006 by the American College of Cardiology Foundation
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slatelets play a major role in the pathophysiology of acute
yocardial infarction (MI) because they adhere to the vessel
all at the site of a vulnerable coronary plaque, and initiate
hrombotic occlusion of the coronary vessel leading to
yocardial ischemia and infarction (1). At the initial stages
f MI, circulating platelets exposed to subendothelial col-
agen are activated and secrete several thrombotic and
roinflammatory molecules (1). Soluble CD40 ligand
sCD40L), an important proinflammatory molecule se-
reted by activated platelets (2), is also involved in plaque
estabilization (3,4) and thrombus formation (5,6) during
he acute phase of MI.
Platelet adhesion to subendothelial collagen during acute
oronary syndromes is mediated by specific receptors (inte-
rins) on their surface, such as glycoproteins Ia/IIa (GPIa/
Ia) (1,7–9) and VI (GPVI) (9). Therefore, as a platelet
eceptor for collagen, GPIa/IIa plays an important role in
latelet adhesion and activation during MI (10). Two
From the Athens University Medical School, 1st Cardiology Department, Hip-
okration Hospital, Athens, Greece. The first two authors contributed equally to this
tudy.t
Manuscript received September 20, 2005; revised manuscript received November
8, 2005, accepted December 5, 2005.enetic polymorphisms on GPIa, the C807T and A1648G,
ave been associated with increased cardiovascular risk in
ome populations (11,12), although their role is largely
ontroversial (13,14). The presence of 807T allele has been
ssociated with increased expression of GPIa on platelet
urface (15) and increased thrombogenicity (16), despite the
act that it does not affect the molecular structure of GPIa.
1648A polymorphism on GPIa gene leads to a Glu/
ys505 substitution in GPIa molecule, and it is responsible
or the human platelet alloantigen system Bra/Brb (17), but
ts effect on the functional status of GPIa is unclear.
In the present study, we examined the potential role of
807T and G1648A polymorphisms of platelet GPIa, as
isk factors for the development of premature MI. We also
xamined whether the presence of these polymorphisms
odifies platelet activation and affects the release of
CD40L during the acute phase of premature MI, as well as
ne year after the event in the same patients, and in healthy
ndividuals. Moreover, we examined the ability of von
illebrand factor (vWF) (a surrogate marker of endothelial
njury and activation [18] and a direct stimuli for the platelet
urface translocation of CD40L [19]) to modify the effect of
hese two polymorphisms on the release of sCD40L.
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tudy population. This study enrolled a total number of
06 subjects: 219 patients of both genders with a first event
f premature MI, and 387 controls of similar age and gender
Table 1). Patients aged 49 years old, consecutively
dmitted to coronary care unit with a first event of ST-
egment elevated myocardial infarction (STEMI) were re-
ruited. The diagnosis of STEMI was defined according to
he guidelines (20). All patients were thrombolized and
eceived the same standard therapy including aspirin, low-
olecular-weight heparin, statin, intravenous nitrates, and
ngiotensin-converting enzyme inhibitors as appropriate.
Controls had no clinical evidence of coronary heart
isease, stroke, or any atherosclerotic disease (based on a
etailed medical history, physical examination followed by
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CI  confidence interval
GPIa  glycoprotein Ia
GPVI  glycoprotein VI
HDL  high-density lipoprotein
MI  myocardial infarction
PCI  percutaneous coronary intervention
sCD40L  soluble CD40 ligand
STEMI  ST-segment elevated myocardial infarction
vWF  von Willebrand factor
Table 1. Demographic Characteristics and Gen
MI C
Number of subjects 21
Age (yrs) 47.97
Gender (male/female) 205
Current smokers/ex-smokers 195
Hypercholesterolemia, n (%) 116 (5
Hypertension, n (%) 90 (4
Diabetes mellitus, n (%) 25 (1
BMI (kg/m2) 27.84
Cholesterol levels (mg/dl) 251.42
HDL (mg/dl) 35.83
Triglycerides (mg/dl)* 138 (9
Fasting glucose (mg/dl) 115.42
Genotype distribution C807T
807CC, n (%) 73 (3
807CT, n (%) 112 (5
807TT, n (%) 34 (1
Recessive model
807TT, n (%) 34 (1
807CC  807CT, n (%) 185 (8
A1648G
1648GG, n (%) 161 (7
1648AG, n (%) 50 (2
1648AA, n (%) 8 (3
Recessive model
1648AA, n (%) 8 (3
1648GG  1648AG, n (%) 211 (9
Values expressed as means SEM. *Value expressed as media
after adjustment for age, gender, and classic risk factors.
BMI  body mass index; HDL  high-density lipoprotein; Mlectrocardiogram). All patients and controls were Greek
aucasians, habitants of Athens in Greece. Demographic
haracteristics are presented in Table 1.
rotocol. The study was approved by the institutional
thics committee, and an informed consent was given by all
he participants. Blood samples were obtained at the 24th h
fter admission for genotyping and for evaluation of serum
evels of sCD40L and plasma levels of vWF. All patients
ere followed up prospectively for one year, and a well-
efined group of patients with a stable clinical condition for
t least the previous six months was recalled for the
ollow-up study one year after the event, and new blood
amples were obtained. Exclusion criteria from the
ollow-up study were the existence of any inflammatory or
nfective disease, liver or renal disease, malignancy, heart
ailure defined as ejection fraction 45%, history of deep
ein thrombosis or pulmonary embolism, while patients
eceiving non-steroid or anti-inflammatory drugs or antico-
gulants (other than aspirin) were also excluded. To avoid
ossible influences of percutaneous coronary intervention
PCI), catheter-related acute phase reactions, or coronary
rtery bypass grafting (CABG) operation on the measured
arameters during the acute phase of MI or at the follow-
p, patients who required urgent PCI, coronary angio-
raphic investigation, or CABG within the first 24 h of the
vent or 6 months before the follow-up study were also
xcluded. None of the patients included in the follow-up
tudy received GPIIb/IIIa antagonists during and after the
e Distribution
Control Subjects p Value
387
6 46.85  0.41 0.229
354/33 0.218
220/13 0.0001
121 (31.3) 0.0001
127 (32.8) 0.043
43 (11.1) 0.548
58 26.87  0.22 0.006
75 227.34  2.60 0.0001
3 47.61  1.51 0.0001
) 112 (75–146) 0.0001
05 91.88  1.12 0.0001
143 (36.9)
214 (55.3)
30 (7.8)
0.014†
30 (7.8)
357 (92.2)
300 (77.6)
77 (19.9)
10 (2.6)
0.395†
10 (2.6)
377 (97.4)
h–75th percentile values); †Indicates p by chi-square analysisotyp
ases
9
 0.6
/14
/4
2.9)
1.1)
1.4)
 0.2
 52.
 0.6
9–193
 52.
3.3)
1.2)
5.5)
5.5)
4.5)
3.5)
2.8)
.7)
.7)
6.3)
n (25tI  myocardial infarction.
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May 16, 2006:1959–66 Polymorphisms of Platelet GPIa and MIcute MI. Of the 219 MI patients in the first part of the
tudy, 76 fulfilled the inclusion criteria for the follow-up
tudy, and 67 of them agreed to participate. All patients
ere under standard medication as appropriate.
The control group in the follow-up study consisted of 232
ndividuals selected from the initial study cohort to have
imilar age, gender, and the major risk factors as the patient
roup (Table 1). This design allows safer comparisons
etween the groups, because it diminishes any effect of the
nderlying risk factors on the expression of sCD40L and
ndothelial activation. All the control subjects had no
vidence of cardiovascular disease (such as coronary artery
isease or stroke), and they had normal electrocardiograms
nd exercise stress tests. The same general exclusion criteria
sed for patients were also applied to the control group. All
he participants in the follow-up study were asked to abstain
rom tobacco, alcohol, and caffeine-containing beverages
uring the evening before blood sampling, and they discon-
inued their medication for 12 h before the study. Venous
lood samples were centrifuged at 3,500 rpm at 4°C for 15
in, and plasma or serum was collected and stored at
80°C until assayed.
iochemical measurements. Routine chemical methods
ere used to determine serum concentrations of total
holesterol, high-density lipoprotein (HDL), and triglycer-
des. Enzyme linked immunosorbent assays were used for
he determination of plasma levels of vWF (Asserachrom,
iagnostica Stago, Asnières sur Seine, France), and
CD40L (Bender Medsystems, Vienna, Austria).
NA extraction and genotyping. Genomic deoxyribonu-
leic acid was extracted from 2 to 5 ml of whole blood using
tandard methods (QIAamp DNA blood kit, Qiagen,
ermantown, Maryland). The detection of C807T polymor-
hism on GPIa gene was performed by polymerase chain
eaction as previously described (11,21), with the following
rimers: sense 5=-ACCTTGCATATTGAATTGCTT-3=
nd antisense 5=-GTGTTTAACTTGAACACATAT-3=,
nd the polymerase chain reaction products were digested by
he TaqI restriction enzyme (New England BioLabs, Ipswich,
assachusetts). Digested fragments were visualized on 3%
garose gel, after ethidium bromide staining under ultraviolet
ight. Similarly, G1648A polymorphism was detected using
he following primers: sense 3=-GTTGATGTGGATAAA
ACACC-5= and antisense 3=-ATGATGAAATGTAA
CCATAC-5=, and the polymerase chain reaction products
ere digested by Mnl I restriction enzyme (New England
iolabs), electrophoresed with 2.5% agarose gel, and visualized
nder ultraviolet using ethidium bromide staining, as previ-
usly described (12).
tatistical analysis. We tested the allele frequencies con-
ormed to Hardy-Weinberg equilibrium proportions by use
f the chi-square test. According to the applied power
nalysis based on previous reports (22), a total sample size of
30 subjects (cases and controls) was adequate to detect at
east a 15% difference in the frequency of the examined
lleles between groups, achieving statistical power 90% at a 0.05 probability level (p value). The number of both
ases and controls was, however, increased (n  606) to
ermit further analyses in subgroups. Qualitative variables
re presented as absolute and relative frequencies. Genotype
nd allele frequencies were compared between groups by
hi-square analysis, and conditional multiple logistic regres-
ion analysis was used to estimate odds ratios and 95%
onfidence intervals (CI), of the development of MI as a
unction of C807T or A1648G polymorphisms. All odds
atios were adjusted for age, gender, and atherosclerosis risk
actors, such as hypertension, diabetes mellitus, hypercho-
esterolemia, obesity, and smoking. Continuous variables
ere tested for normal distribution by the Kolmokorov-
mirnov test. Normally distributed variables are presented
s mean values  SEM, while not normally distributed
ariables were log-transformed for analysis and are pre-
ented in the non-logarithmic format as median (25th to
5th percentiles values). The log-transformed variable (tri-
lyceride levels) was confirmed to have normal distribution.
omparisons of continuous variables between patients and
ontrols or between the genotypes were performed by the
npaired Student t test if normally distributed, or by the
ann-Whitney U test if non-normally distributed. The
hange of sCD40L from baseline (acute phase) to the
ne-year follow-up value and the comparison of this change
etween the different genotype groups was assessed by
nalysis of variance (ANOVA) for repeated measurements.
omparisons of the sCD40L level between the “control
roup” and the “group of patients during the acute phase” or
etween the “control group” and the “group of patients at
ollow-up” were performed by using ANOVA for multiple
omparisons followed by Bonferroni correction.
Stepwise multivariate analysis was undertaken with
CD40L as dependent variable and clinical factors (age,
ender, hypertension, diabetes, smoking, hypercholesterol-
mia, and obesity, cholesterol levels, triglyceride levels,
DL levels) and C807T or A1648G polymorphisms as
ndependent variables. We included as independent vari-
bles in each multivariate model the respective polymor-
hism (CC/CT  TT for C807T or GG/AG  AA for
1648G) as well as those that showed a significant associ-
tion with the dependent variable in univariate analysis, at
5% significance level. A backward elimination procedure
as applied in all multivariate models (using p 0.05 as the
hreshold for removing a variable from the model).
All reported p values are based on two-sided tests and
ompared with a significance level of 5%. SPSS version 12.0
SPSS Inc., Cary, North Carolina) software was used for all
he statistical calculations.
ESULTS
linical characteristics and genotype distribution. The
tudy population consisted of 606 subjects. The population
haracteristics, serum lipid and glucose levels at baseline,
nd genotype frequencies are presented in Table 1. There
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Polymorphisms of Platelet GPIa and MI May 16, 2006:1959–66as a significant difference in the prevalence of 807TT geno-
ype in cases compared with controls (p 0.05) (Table 1). The
isk for MI in TT was significantly increased compared
ith all the other genotypes (Table 2), and remained
ignificantly elevated after adjustment for age, gender,
nd classic risk factors (Table 2). On the other hand,
lthough the prevalence of 1648AA genotype in cases was
lightly higher compared with controls, this difference
id not reach statistical significant, even after adjustment
or age, gender, and classic risk factors for atherosclerosis
Tables 1 and 2).
The angiographic extent of coronary artery disease in
atients as well as demographic characteristics, genotype
istribution, lipid levels, and medication of patients and
ontrols in the follow-up study are presented in Table 3. In
he patient group, 14 had CABG operation and 29 had PCI
t least six months before the follow-up study, while there
as no difference in genotype distribution among those
atients.
olymorphisms C807T and A1648G and sCD40L vari-
tions during MI. Serum levels of sCD40L were signifi-
antly increased during the acute phase of MI in both
arriers of 807T (807TT  807CT) allele (by 4.12 g/l
95% CI: 3.00 to 5.24] p  0.0001 vs. follow-up) and in
07CC homozygotes (by 2.36 g/l [95% CI: 1.0.81 to
.638] p  0.001 vs. follow-up). The change in sCD40L
rom rest to the value during the acute phase of MI was
reater among the carriers of the T allele compared with
07CC homozygotes (p  0.05). Furthermore, sCD40L
evel was significantly higher in carriers of the 807T allele
ompared with 807CC homozygotes, both during the acute
hase of MI and at follow-up (Fig. 1). Carriers of the 807T
llele had higher levels of sCD40L both during the acute
hase of MI and one year after the event, compared with
ealthy controls (p  0.01 for both vs. control, after
onferroni correction) (Fig. 1). However, patients with
07CC genotype had higher levels of sCD40L compared
ith healthy individuals only during the acute phase of MI,
ut not one year after the event (p 0.05 for acute phase vs.
ontrol subjects, after Bonferroni correction) (Fig. 1).
Table 2. Odds Ratios as Estimates of Relative
Carriers of 807T and 1648A Alleles
Genotypes Crude Odds Ratios (95%
C807T
TT vs. CC  CT 2.187 (1.298–3.686)
TT vs. CC 2.220 (1.260–3.911)
TT vs. CT 2.165 (1.260–3.722)
CT vs. CC 1.025 (0.713–1.474)
A1648G
AA vs. GG  AG 1.429 (0.556–3.677)
AA vs. GG 1.491 (0.577–3.851)
AA vs. AG 1.232 (0.455–3.334)
AG vs. GG 1.210 (0.808–1.813)
p values by chi-square analysis. *Adjusted for age, gender, an
CI  confidence interval.mong healthy individuals, there was no significant differ- snce in sCD40L levels between carriers of 807T and
07CC homozygotes (Fig. 1). Healthy individuals were
ivided according to median vWF levels (median [25th to
5th percentile] for healthy controls: 72.84% [52.35 to
0.96]), to examine whether the effect of C807T polymor-
hism on the release of sCD40L was dependent on the
egree of endothelial damage. Indeed, it was found that
lthough there was no significant difference in sCD40L
etween genotypes among subjects with vWF  median
mean vWF: 50.5  1.2%), in the presence of high vWF
evels (vWFmedian, mean vWF: 97.7 2.1%) carriers of
07T allele had significantly higher levels of sCD40L
ompared with 807CC homozygotes (p  0.05) (Fig. 2a).
mong patients at follow-up, carriers of the 807T allele had
igher levels of sCD40L compared with 807CC indepen-
ently from vWF levels (median [25th to 75th percentile] of
WF at follow-up: 87.1% [72.84 to 96.60]), as presented in
igure 2b. Similarly, carriers of the 807T allele also had
igher levels of sCD40L during the acute phase of MI
ompared with 807CC, independently from vWF levels
median [25th to 75th percentile] of vWF levels during the
cute phase: 92.12% [71.1 to 112.0]).
Serum levels of sCD40L during the acute phase of MI were
imilar between carriers of the 1648A allele (1648AA 
648AG) (10.80  2.57 g/l) and 1648GG homozygotes
11.17  1.09 g/l, p  NS), while one year after the event
here was still no difference in sCD40L levels between the
enotypes (7.94 1.80 g/l in 1648A carriers vs. 7.26 0.86
g/l in 1648GG, p  NS). Similarly, among healthy individ-
als, carriers of 1648A allele had similar levels of sCD40L
4.87  0.65 g/l) compared with 1648GG homozygotes
5.19  0.28 g/l, p  NS), although significantly lower
han patients during the acute phase (p  0.01 for all
enotypes) or at follow-up (p  0.05 for all genotypes).
lasma levels of vWF did not modify the potential effect of
1648G polymorphism on the variations of sCD40L in any
f the study groups.
ultivariate analysis. In multivariate analysis, it was
ound that during the acute phase of premature MI, the
resence of 807T allele was an independent predictor for
for Premature Myocardial Infarction in
p Value Odds Ratios (95% CI)* p Value
0.003 2.296 (1.187–4.440) 0.014
0.006 2.269 (1.085–4.745) 0.030
0.005 2.135 (1.080–4.219) 0.029
0.893 0.991 (0.626–1.568) 0.968
0.459 1.820 (0.459–7.219) 0.395
0.410 1.888 (0.460–7.750) 0.378
0.681 1.630 (0.415–6.404) 0.484
0.355 1.018 (0.603–1.718) 0.946
sic risk factors.Risk
CI)CD40L levels (  9.442 [SE: 2.526], p  0.001). Other
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May 16, 2006:1959–66 Polymorphisms of Platelet GPIa and MIredictors of sCD40L levels during the acute phase of MI
ere smoking (  8.206 [SE: 3.204], p  0.014), diabetes
ellitus (  10.207 [SE: 4.359], p  0.024), and obesity
  4.758 [SE: 2.114], p  0.030). In the same subjects
ne year after the event, the presence of the 807T allele was
till an independent predictor for sCD40L levels ( 8.282
SE: 2.044], p  0.001), as well as diabetes mellitus ( 
.843 [SE: 3.523], p  0.031) and obesity (  4.463 [SE:
.714], p  0.013). Among healthy controls, the presence
f T allele was not an independent predictor for sCD40L
evels.
ISCUSSION
n the present study, we examined the effect of genetic
olymorphisms C807T and A1648G of platelet GPIa, on
he risk for premature MI. We have shown that only C807T
olymorphism is independently associated with increased
isk for MI. We have also shown that the presence of 807T
Table 3. Demographic Characteristics, Medica
Participants in the Follow-Up Study
Number of subjects
Distribution of C807T
CC/CT/TT
Distribution of A1648G
GG/AG/AA
Demographic characteristics
Age (yrs)
Gender (male/female)
Hypercholesterolemia, n (%)
Active smokers, n (%)
Hypertension, n (%)
Diabetes mellitus, n (%)
BMI (kg/m2)
Cholesterol levels (mg/dl) 1
HDL (mg/dl)
Triglycerides (mg/dl) 13
Fasting glucose (mg/dl) 1
Medication
Nitrates, n (%)
Angiotensin receptor antagonists, n (%)
Angiotensin-converting enzyme
inhibitors, n (%)
Diuretics, n (%)
Calcium-channels inhibitors, n (%)
Beta-blockers, n (%)
Statins, n (%)
Anti-diabetic medication, n (%)
Aspirin, n (%)
Amiodarone, n (%)
Extend of CAD at baseline
(vessels with 50% stenosis)
1 vessel
2 vessels
3 vessels
CABG operation after the event, n (%)
PCI after the event, n (%)
Values expressed as mean  SEM or median (25th–75th pe
BMI  body mass index; CABG  coronary artery byp
high-density lipoprotein; MI  myocardial infarction; PCIllele is an independent predictor for the release of sCD40L (uring the acute phase of MI, an effect that persists in the
ame patients one year after the event. In healthy subjects,
he presence of 807T allele was associated with increased
evels of sCD40L only in the presence of high vWF levels.
enetic polymorphisms C807T and G1648A on platelet
PIa, and the risk for premature MI. Evidence suggests
hat platelet GPIa/IIa (integrin 21) and GPVI (9) are
ajor platelet receptors for collagen (7,8). Glycoprotein
a/IIa also modifies the GPIb-IX, vWF axis (8) and
articipates in platelet adhesion to subendothelial collagen
nd activation. Therefore, any variation in platelet GPIa
ensity could become a potential risk factor for hemostatic
bnormalities (8). Kunicki et al. (23) first described that
enetic polymorphisms within the GPIa gene are associated
ith variations in platelet GPIa/IIa expression levels. Silent
olymorphism C807T (codon Phe224) in GPIa gene affects
he density of this integrin on platelets surface, in a way that
07T allele expresses higher levels of GPIa than 807C allele
and Genotype Distribution Among the
Cases Control Subjects p Value
67 232
/33/14 84/127/21
/13/3 182/40/10
 0.76 50.60  0.81 0.253
3/4 213/19 0.795
7.7) 74 (31.9) 0.042
7.3) 128 (55.2) 0.001
6.2) 94 (40.5) 0.575
3.4) 36 (15.5) 0.702
 0.43 26.53  0.26 0.186
 6.00 178.25  2.17 0.237
 1.71 47.46  1.89 0.293
03.5–166.0) 112.0 (80.0–154.0) 0.013
 6.13 91.21  1.58 0.0001
.0) 0 (0) 0.050
2.4) 19 (8.2) 0.003
2.7) 70 (30.2) 0.001
5.8) 53 (23.3) 0.039
1.9) 11 (4.7) 0.045
8.7) 14 (6.0) 0.001
0.1) 76 (32.8) 0.001
3.4) 33 (14.2) 0.870
8.5) 33 (14.2) 0.001
.0) 0 (0)
2.2) —
8.3) —
9.4) —
5.3) —
3.2) —
le values) unless indicated otherwise.
afting operation; CAD  coronary artery disease; HDL 
utaneous coronary intervention.tion,
MI
20
51
48.51
6
32 (4
25 (3
31 (4
9 (1
27.15
85.29
42.51
5.0 (1
09.61
2 (3
15 (2
42 (6
24 (3
9 (1
46 (6
47 (7
9 (1
66 (9
2 (3
35 (5
19 (2
13 (1
14 (2
29 (4
rcenti15,24). On the other hand, G1648A polymorphism leads
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Polymorphisms of Platelet GPIa and MI May 16, 2006:1959–66o a Glu/Lys505 substitution in the GPIa molecule, and it is
esponsible for the human platelet antigen system Bra/Brb
17). Although these polymorphisms do not affect the
unctional status of GPIa, they seem to influence its density
n the platelet surface (15,25). It has been proposed that
807T polymorphism may affect the stability of mRNA
r it may be linked to genetic alteration(s) located in
egulatory regions of the GPIa gene, while G1648A
ould affect the stability of the protein or the formation of
he GPIa/IIa complex, thus determining the number of
PIa/IIa complexes (14).
Genetic polymorphism C807T has been associated with
he development of stroke (26) or MI in younger individuals
11,27,28) and especially among young smokers (11). Re-
ent evidence suggests that 807T allele may also predict
ecurrent acute coronary syndromes (29), possibly as a result
f the increased thrombogenicity accompanying the pres-
nce of 807T allele. However, other studies failed to
emonstrate such an effect on the risk for MI (13,22,30,31),
r restenosis (32) and events (33) after angioplasty. Simi-
arly, the effect of G1648A polymorphism on the risk for
I is also controversial. The first reports suggested that the
resence of 1648A allele may be a risk factor for MI (12)
lthough this relationship is also questioned (14). Based on
hese controversial reports, it can be hypothesized that other
arameters such as the specific population characteristics may
odify the effect of this polymorphism on the risk for MI.
In the present study, we have shown that only C807T
olymorphism was an independent risk factor for the
evelopment of premature MI. Homozygosity for the 807T
llele was associated with an increased risk for MI (odds
atio: 2.2 compared with 807C homozygotes). These results
igure 1. Serum levels of soluble CD40 ligand (sCD40L) were signifi-
antly higher in carriers of the 807T allele both during the acute phase of
yocardial infarction (MI) and one year after the event in the same
ubjects, compared with 807CC homozygotes. Although sCD40L level
as increased in all genotypes during the acute phase of MI compared with
he values one year after the event, the increase in 807T carriers was greater
han the increase in 807CC homozygotes (p  0.05). Levels of sCD40L
ere similar between the genotypes in the control group. Solid bars 
arriers of the 807T allele (807TT  807CT); open bars  807CC
omozygotes. *p  0.01 vs. CC; †p  0.01 vs. acute phase (after
onferroni correction); ‡p  0.01 vs. controls (after Bonferroni
orrection).ere compatible with previous reports suggesting an in-
a
arease of the risk for MI by 2.6 to 3.3 (11,27) in 807T
omozygotes.
enetic polymorphisms C807T and G1648A on platelet
PIa, and the release of sCD40L during the acute phase
f MI. Platelet activation is a key feature in the pathogen-
sis of acute coronary syndromes (1,34,35). Exposure of
irculating platelets to subendothelial collagen leads to their
ctivation and the secretion of several thrombotic and
roinflammatory molecules during the acute phase of MI
1). Soluble CD40 ligand, an important proinflammatory
olecule secreted by activated platelets (2), is involved in
laque destabilization (3,4) and thrombus formation (3,5,6)
uring the acute phase of MI (3,6). In addition, ligation of
D40 mediates an array of proinflammatory effects in
ubjects with risk factors for atherosclerosis such as smokers
36), patients with diabetes mellitus (37) or hypercholester-
lemia (38), including the expression of cytokines, chemo-
ines, adhesion molecules, matrix metalloproteinases, and
rowth factors (2,39), and it is a strong predictor for clinical
utcome in patients with advanced atherosclerosis (3). It has
igure 2. (A) In the control group, carriers of the 807T allele (807TT 
07CT) had significantly higher levels of soluble CD40 ligand (sCD40L)
ompared with 807CC homozygotes in the presence of high levels of von
illebrand factor (vWF  median), while there was no difference in
CD40L between genotypes among healthy individuals with vWF 
edian (vWF median in controls: 72.84%). (B) Carriers of the 807T allele
ad significantly higher levels of sCD40L compared with 807CC one year
fter myocardial infarction (MI) independently from plasma vWF levels
vWF median for follow-up group: 87.1%). (C) Similarly, the presence of
he 807T allele was associated with higher levels of sCD40L during the
cute phase of MI, independently from vWF levels (median for vWF
uring the acute phase of MI: 92.12%). Solid bars  Carriers of the 807T
llele (807TT  807CT); open bars  807CC homozygotes; *p  0.05
nd **p  0.01 vs. carriers of T allele.
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May 16, 2006:1959–66 Polymorphisms of Platelet GPIa and MIeen recently reported by Schafer et al. (40) that a decrease
f nitric oxide production in healthy volunteers increases
D40L expression on the platelet surface, suggesting that
ascular endothelium is a key regulator of platelet CD40L
xpression.
Platelet activation is partly mediated by the adhesion to
ubendothelial collagen, an effect mediated by GPIa (7,8).
n vitro evidence suggests that 807T allele of GPIa gene is
ssociated with increased platelet reactivity (41) possibly due
o its effect on the density of GPIa on platelets surface, an
ffect confirmed at a clinical level, in platelets from patients
fter CABG (42). However, the effect of GPIa and its
enetic polymorphisms on the release of sCD40L has not
een investigated until now.
In the present study, we hypothesized that GPIa may
nfluence the release of sCD40L during the acute phase of
I, due to its role in the platelet-collagen interactions
eading to platelet activation, and we examined whether
807T polymorphism (which modifies the density of GPIa
n platelet surface) could affect sCD40L levels during the
cute phase of premature MI. Moreover, in order to
xamine the ability of endothelial integrity to mask the
ffect of C807T on the release of sCD40L, we divided the
ontrol group according to plasma levels of vWF (a marker
f endothelial cell integrity) (18). We found that the
resence of 807T allele was an independent predictor of
CD40L during the acute phase of MI, an effect persisting
although in a lower degree) in the same subjects one year
fter the event. Interestingly, we also found that even in the
ontrol group, carriage of the 807T allele was associated
ith higher levels of sCD40L compared with 807C ho-
ozygotes only among those with vWF greater than or
qual to the median, an effect not observed among those
ith vWF less than the median. This finding suggests that
he presence of the 807T allele may participate in the
athogenesis of atherosclerosis and acute coronary syn-
romes only in the presence of endothelial damage, where
latelet-collagen interactions have a significant contribution
o platelet activation. A possible explanation for this effect is
hat endothelial injury and exposure of subendothelial col-
agen to circulating platelets seems to be the necessary
ynamic precondition for any effect of C807T polymor-
hism or platelet GPIa density on the variability of
CD40L. As described by Tamura et al. (19), vWF can also
nduce CD40L expression on platelet surface especially
nder increased sympathetic stimulation that is present
uring MI. It is also likely that vWF-induced CD40L
xpression occurs in platelets adhering to exposed subendo-
helial matrix substances, such as collagen, and that the
WF-GPIb-alpha interaction induces thrombus formation
n the collagen surface. Although existing evidence suggests
hat vWF induces CD40L expression by binding to GPIb-
lpha (43), it is also likely that the elevation of vWF
bserved during MI (44) could induce higher platelet
eactivity/activation and release of sCD40L in the presence
f 807T allele in GPIa gene, because this glycoprotein
1odifies the GPIb-IX-vWF axis (8), although the under-
ying mechanisms require further investigation.
onclusions. In the present study, we have shown that
807T but not G1648A polymorphism of platelet GPIa
ene is an independent risk factor for premature MI. We have
hown that the presence of 807T allele is an independent
redictor for the variations of sCD40L both during the acute
hase of MI as well as one year after the event in the same
opulation. Furthermore, the presence of 807T allele affects
he release of sCD40L in healthy subjects only in the
resence of higher vWF levels.
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